Vanguard Group Inc. Lowers Stock Holdings in Omeros Co. (NASDAQ:OMER)

Vanguard Group Inc. reduced its holdings in shares of Omeros Co. (NASDAQ:OMER - Free Report) by 3.6% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 3,141,657 shares of the biopharmaceutical company's stock after selling 117,942 shares during the period. Vanguard Group Inc. owned approximately 5.42% of Omeros worth $31,040,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Truvestments Capital LLC increased its stake in Omeros by 116.5% in the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company's stock valued at $31,000 after buying an additional 1,669 shares during the period. Quantbot Technologies LP purchased a new position in Omeros during the fourth quarter worth about $46,000. BNP Paribas Financial Markets lifted its position in Omeros by 130.6% in the third quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company's stock valued at $49,000 after purchasing an additional 7,016 shares during the period. Picton Mahoney Asset Management boosted its holdings in Omeros by 692.5% in the 4th quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company's stock valued at $50,000 after purchasing an additional 4,404 shares in the last quarter. Finally, MML Investors Services LLC raised its stake in shares of Omeros by 19.2% during the 3rd quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company's stock worth $74,000 after buying an additional 3,000 shares in the last quarter. 48.79% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

OMER has been the subject of several research analyst reports. StockNews.com cut Omeros from a "hold" rating to a "sell" rating in a research report on Wednesday, April 9th. D. Boral Capital restated a "buy" rating and set a $36.00 target price on shares of Omeros in a research report on Friday, April 11th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Omeros in a research report on Tuesday, April 1st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $22.50.

Omeros Price Performance

Shares of NASDAQ OMER traded up $0.02 on Friday, hitting $6.78. The company's stock had a trading volume of 423,357 shares, compared to its average volume of 573,890. The stock has a 50 day moving average of $8.05 and a 200-day moving average of $7.80. Omeros Co. has a 12-month low of $2.97 and a 12-month high of $13.60. The company has a market capitalization of $393.67 million, a price-to-earnings ratio of -2.94 and a beta of 2.35.

Omeros (NASDAQ:OMER - Get Free Report) last announced its earnings results on Monday, March 31st. The biopharmaceutical company reported ($0.63) EPS for the quarter, beating analysts' consensus estimates of ($0.71) by $0.08. During the same period last year, the firm posted ($0.15) EPS. Sell-side analysts expect that Omeros Co. will post -3.09 EPS for the current fiscal year.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.